The global Robotic Lung Biopsy Market Sales value is expected to increase from US$ 408.0 Million in 2023 to US$ 1,023.05 Million by 2033. Over the next decade (2023 to 2033), global Robotic Lung Biopsy demand is forecast to surge at 9.6% CAGR.
The Robotic Lung Biopsy industry is driven by several factors. This includes the minimally invasive nature of robotic lung biopsies, the growing demand for personalized medicine, and the increasing prevalence of lung cancer.
Robotic Lung Biopsy refers to a minimally invasive procedure performed using robotic-assisted technology to obtain tissue samples from the lungs for diagnostic purposes. It involves the use of a robotic system, typically controlled by a surgeon, to guide the biopsy needle to the targeted lung lesion.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-17225
During a Robotic Lung Biopsy, the patient is placed under general anesthesia. The surgeon makes small incisions in the chest, through which robotic arms with specialized instruments and a camera are inserted. The surgeon controls the robotic system from a console, manipulating the instruments with precision and accuracy.
Lung cancer is one of the leading causes of cancer-related deaths worldwide. As the incidence of lung cancer continues to rise, there is a growing demand for advanced diagnostic and treatment methods. This includes Robotic Lung Biopsy, which can accurately diagnose lung tumors and guide treatment decisions.
Robotic Lung Biopsy procedures are minimally invasive compared to open surgical biopsies. They involve smaller incisions, reduced trauma to the patient, and faster recovery times. This less invasive approach appeals to both patients and healthcare providers, leading to increased adoption of Robotic Lung Biopsy techniques.
There is also a growing focus on personalized medicine, which aims to provide tailored treatment options based on individual patient characteristics. Robotic Lung Biopsy plays a crucial role in obtaining tissue samples for molecular testing, which helps identify specific genetic mutations or biomarkers that can guide targeted therapies.
The increasing demand for personalized medicine is expected to drive the growth of the Robotic Lung Biopsy industry during the assessment period.
Robotics is being increasingly integrated into various aspects of healthcare, including surgery and diagnostics. As the adoption of robotic systems in healthcare continues to expand, the global Robotic Lung Biopsy industry is set to expand at a robust pace.
Key Takeaways:
- Global demand for robotic lung biopsies is projected to increase at 9.6% CAGR from 2023 to 2033.
- The instruments and accessories segment is expected to progress at 10.9% CAGR through 2033.
- Based on navigation technology, the fiber optic realshape navigation segment is expected to thrive at 10.4% CAGR.
- The United States Robotic Lung Biopsy industry in the United States is predicted to reach US$ 648.1 million by 2033.
- Robotic Lung Biopsy demand in the United Kingdom is forecast to expand at a CAGR of 8.2% through 2033.
- The Robotic Lung Biopsy industry in China is expected to reach US$ 23.4 million by 2033.
- Sales in Japan market are likely to soar at 9.7% CAGR from 2023 to 2033.
- South Korea’s Robotic Lung Biopsy industry is projected to thrive at 5.5% CAGR during the forecast period.
Who is Winning?
There are several players competing for market share in the fiercely competitive Robotic Lung Biopsy market. Among other firms, important players in this market are Ethicon, Inc. (Johnson & Johnson) and Intuitive Surgical.
Key businesses are particularly spending money on research and development projects to develop innovative goods with increased effectiveness, dependability, and affordability. To fulfill evolving customer demands, they are also focusing on expanding their product line and supporting their end users.
Strategic partnerships and affiliations with other businesses are becoming more common in the industry, allowing firms to capitalize on one another’s strengths and increase their market share.
Leading firms also use consolidation and mergers to strengthen their position in the market and get access to new markets. In emerging markets, particularly in countries like China and India, the sector is notably expanding. To achieve a competitive advantage, they are concentrating on providing clients in these markets with cost-effective solutions.
Robotic Lung Biopsy Market Recent developments:
- In February 2023, to quickly detect lung cancer, a new robotic platform was unveiled by Lee Health.
Key Players:
- Ethicon, Inc. (Johnson & Johnson)
- Intuitive Surgical
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-17225
More Insights Available:
Future Market Insights (FMI), in its new offering, presents an unbiased analysis of the Robotic Lung Biopsy market presenting historical data (2018 to 2022) and forecast statistics for the period from 2023 to 2033.
Robotic Lung Biopsy Market Segmentation:
By Product and Services:
- System
- Instruments and Accessories
- Service
By Navigation Technology:
- Electromagnetic and Optical Navigation
- Fiber Optic RealShape Navigation
By End User:
- Hospitals
- Ambulatory Surgical Centers
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube